Development of a Novel CD26-Targeted Chimeric Antigen Receptor T-Cell Therapy for CD26-Expressing T-Cell Malignancies

Chimeric-antigen-receptor (CAR) T-cell therapy for CD19-expressing B-cell malignancies is already widely adopted in clinical practice. On the other hand, the development of CAR-T-cell therapy for T-cell malignancies is in its nascent stage. One of the potential targets is CD26, to which we have deve...

Descripción completa

Detalles Bibliográficos
Autores principales: Kobayashi, Eiji, Kamihara, Yusuke, Arai, Miho, Wada, Akinori, Kikuchi, Shohei, Hatano, Ryo, Iwao, Noriaki, Susukida, Takeshi, Ozawa, Tatsuhiko, Adachi, Yuichi, Kishi, Hiroyuki, Dang, Nam H., Yamada, Taketo, Hayakawa, Yoshihiro, Morimoto, Chikao, Sato, Tsutomu
Formato: Online Artículo Texto
Lenguaje:English
Publicado: MDPI 2023
Materias:
Article
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC10453178/
https://www.ncbi.nlm.nih.gov/pubmed/37626869
http://dx.doi.org/10.3390/cells12162059

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC10453178/
https://www.ncbi.nlm.nih.gov/pubmed/37626869
http://dx.doi.org/10.3390/cells12162059

Ejemplares similares